BFC Planning’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.13K Sell
100
-100
-50% -$4.69K ﹤0.01% 2866
2026
Q2
$10.7K Hold
200
– – ﹤0.01% 2336
2026
Q1
$9.6K Hold
200
– – ﹤0.01% 2066
2025
Q4
$13.9K Hold
200
– – ﹤0.01% 1917
2025
Q3
$5.6K Buy
+200
New +$3.98K ﹤0.01% 2154
2025
Q2
– Sell
-75
Closed -$1.3K – 2743
2025
Q1
$1.3K Hold
75
– – ﹤0.01% 2398
2024
Q4
$2.03K Hold
75
– – ﹤0.01% 2280
2024
Q3
$3.29K Buy
+75
New +$2.9K ﹤0.01% 2152

Other funds holding GPCR

BFC Planning's GPCR Position: Q3 2026 in Review

BFC Planning reduced its Structure Therapeutics (GPCR) stake by 50% in Q3 2026, selling an estimated $4.69K and leaving 100 shares worth $3.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

BFC Planning first reported a position in GPCR in Q3 2024 and has held it in 8 quarters since. The position peaked at $13.9K in Q4 2025. 113 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • BFC Planning held 100 shares of Structure Therapeutics worth $3.13K as of Q3 2026.
  • BFC Planning sold 100 Structure Therapeutics shares in Q3 2026, an estimated $4.69K.
  • Structure Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2866 holding.
  • BFC Planning first reported a position in Structure Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's Structure Therapeutics position peaked at $13.9K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.